Zhejiang Jingxin Pharmaceutical (002020) Fundamentals 2026 — P/E 15.2x, Revenue Analysis | SniperIQ
Zhejiang Jingxin Pharmaceutical (002020) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥12.2B, trading at ¥14.14 on the SHZ. This SniperIQ fundamentals page covers Zhejiang Jingxin Pharmaceutical's valuation (P/E 15.2x, P/B 1.9x), profitability (net margin 18.8%), revenue (¥4.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Zhejiang Jingxin Pharmaceutical's market cap?
Zhejiang Jingxin Pharmaceutical (002020) has a market capitalization of approximately ¥12.2B, trading at ¥14.14 on the SHZ. Market cap moves with the live share price.
What is Zhejiang Jingxin Pharmaceutical's P/E ratio?
Zhejiang Jingxin Pharmaceutical's trailing twelve-month P/E ratio is 15.2x, with a price-to-book (P/B) of 1.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Zhejiang Jingxin Pharmaceutical?
Zhejiang Jingxin Pharmaceutical runs a net profit margin of 18.8%, a gross margin of 51.0%, and an operating margin of 21.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Zhejiang Jingxin Pharmaceutical generate?
Zhejiang Jingxin Pharmaceutical reported revenue of ¥4.1B for fiscal year 2025, with net income of ¥758M and earnings per share (EPS) of 0.92. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Zhejiang Jingxin Pharmaceutical pay a dividend?
Zhejiang Jingxin Pharmaceutical offers a trailing dividend yield of about 2.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Zhejiang Jingxin Pharmaceutical financially healthy?
Zhejiang Jingxin Pharmaceutical carries a debt-to-equity ratio of 0.02x and a current ratio of 2.03x, with a market beta of -0.11. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Zhejiang Jingxin Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Zhejiang Jingxin Pharmaceutical (002020) the key facts are: market cap ¥12.2B, P/E 15.2x, revenue ¥4.1B, 52-week range 11.45-22.62. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Zhejiang Jingxin Pharmaceutical's full fundamentals live
Get Zhejiang Jingxin Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.